PHASE-II STUDY OF SUBCUTANEOUSLY ADMINISTERED 5-AZACYTIDINE (NSC-102816) IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA

被引：9

作者：

BELLET, RE

CATALANO, RB

MASTRANGELO, MJ

BERD, D

机构：

[1] Fox Chase Cancer Center, Philadelphia, Pennsylvania

来源：

MEDICAL AND PEDIATRIC ONCOLOGY | 1978年 / 4卷 / 01期

关键词：

5‐azacytidine; chemotherapy; melanoma;

D O I：

10.1002/mpo.2950040104

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC‐45388) and a nitrosourea were treated with 5‐azacytidine (NSC‐102816). 5‐Azacytidine was administered subcutaneously at a dosage of 100 mg/m2/day for 10 days. Twenty‐six (26) patients were evaluable for toxicity and response. Major organ toxicities were hematologic, gastrointestinal, and cutaneous; no antitumor activity was noted. Copyright © 1978 Wiley‐Liss, Inc., A Wiley Company

引用

页码：11 / 15

页数：5

共 12 条

[1]

Piskala A, Sorm F, Nucleic acids components and their analogues. LI. Synthesis of 1‐glycosyl derivatives of 5‐azauracil and 5‐azacytosine, Collection of Czechoslovak Chemical Communications, 29, pp. 2060-2076, (1964)

[2]

Hanka LJ, Evans JS, Mason DJ, Dietz A, Microbiological production of 5‐azacytidine. I. Production and biological activity, Antimicrob Agents Chemother, 1, pp. 619-624, (1966)

[3]

Raska K, Jurovocik M, Fucik V, Tykva R, Sormova Z, Sorm F, Metabolic effects of 5‐azacytidine in isolated nuclei of calf‐thymus cells, Collection of Czechoslovak Chemical Communications, 31, pp. 2809-2815, (1966)

[4]

Vesely J, Cihak A, Sorm F, Biochemical mechanisms of drug resistance. IV. Development of resistance to 5‐azacytidine and simultaneous depression of pyrimidine metabolism in leukemic mice, Int J Cancer, 2, pp. 639-646, (1967)

[5]

Paces V, Doskocil J, Sorm F, Incorporation of 5‐azacytidine into nucleic acids of Escherichia coli, Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis, 161, pp. 352-360, (1968)

[6]

Zadrazil S, Fucik V, Vartle P, Sormova Z, Sorm F, The structure of DNA from Escherichia coli cultured in the presence of 5‐azacytidine, Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis, 108, pp. 701-703, (1965)

[7]

Venditti JM, Treatment schedule dependency of experimentally active antileukemic (L1210) drugs, Cancer Chemother Rep, 2, pp. 35-59, (1971)

[8]

Von Hoff DD, Slavik M, Muggia FM, 5‐Azacytidine: A new anticancer drug with effectiveness in acute myelogenous leukemia, Ann Intern Med, 85, pp. 237-245, (1976)

[9]

Bellet RE, Mastrangelo MJ, Engstrom PF, Strawitz JG, Weiss AJ, Yarbro JW, Clinical trial with subcutaneously administered 5‐azacytidine (NSC‐102816), Cancer Chemother Rep, 58, pp. 217-222, (1974)

[10]

Troetel WM, Weiss AJ, Stambaugh JE, Laucius JF, Manthei RW, Absorption, distribution, and excretion of 5‐azacytidine (NSC‐102816) in man, Cancer Chemother Rep, 56, pp. 405-411, (1972)

← 1 2 →